Abbreviations
=============

AICD

:   activation-induced cell death

ACT

:   adoptive cell therapy

BTLA

:   B- and T-lymphocyte attenuator

GB

:   granzyme B, Perf, perforin

TIL

:   tumor-infiltrating lymphocyte

ITIM

:   immunotyrosine-based inhibitory motif

KIR

:   killer-cell immunoglobulin-like receptor

TN

:   naïve T cell

T~CM~

:   central memory T cell

T~EM~

:   effector-memory T cell

T~EMRA~

:   terminally-differentiated CD45RA-expressing T cell

Introduction {#s0001}
============

Adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has emerged as a promising treatment for metastatic melanoma. Multiple institutions, including our group at M.D. Anderson Cancer Center, are conducting Phase II studies for patients with Stage IIIc/IV metastatic melanoma with reported clinical response rates between 45% and 51%.[@cit0001] Identification of TIL subsets associated with clinical response is a critical biomarker for ACT. We previously reported that a positive clinical response to ACT was significantly related to the quantity and frequency of CD8^+^ cytotoxic T cells in the TILs infused into patients.[@cit0002] However, not all patients infused with a majority of CD8^+^ TIL were responders, therefore identification of more specific CD8^+^ subsets is critical, especially to further define the mechanism of action of CD8^+^ T cells during ACT. Moreover, identification of active CD8^+^ TIL subsets could lead to efforts to selectively expand these T cells prior to infusion into patients, which has a high potential to further improve the clinical efficacy of ACT.[@cit0004] Unexpectedly, we found that higher frequencies and numbers of CD8^+^ TILs expressing B- and T-lymphocyte attenuator (BTLA) were significantly correlated to positive clinical responses to ACT.[@cit0002] This was surprising as BTLA has been described as a coinhibitory receptor with an immunotyrosine-based inhibitory motif (ITIM) and an immunotyrosine-based switch motif (ITSM), similar to the well-known inhibitory receptors PD-1 and CTLA-4.[@cit0005] Like PD-1, BTLA has been shown to inhibit proliferation and cytokine production in melanoma tumor antigen-specific CD8^+^ T cells by recruitment of SHP1/2 phosphatases.[@cit0006] However, recent studies by other groups have found that BTLA may also promote cell survival by inducing a gene expression program similar to that induced by ICOS and CD28 costimulation.[@cit0008]

Although BTLA has been characterized as a negative costimulatory molecule on T cells, a number of studies of human CD8^+^ T cells have shown that BTLA is constitutively expressed at a high level on naïve CD8^+^ T cells and gradually downregulated during T-cell expansion and cytotoxic T lymphocyte (CTL) differentiation.[@cit0006] A recent study suggested a close relationship between the expression of multiple inhibitory receptors (e.g., PD-1, TIM3, and LAG3) and antigen specificity, anatomic localization, and differentiation of CD8^+^ T cells in humans.[@cit0012] Therefore, it is likely that sustained BTLA expression marks a specific stage of differentiation in human CD8^+^ melanoma TILs.

In this study, we performed comprehensive phenotypic and functional characterization and gene expression profiling of CD8^+^BTLA^+^ TIL isolated and expanded from melanoma metastases in comparison with their CD8^+^BTLA^−^ counterparts. We found that CD8^+^BTLA^+^ TIL were a less-differentiated, highly proliferative CD8^+^ effector memory (T~EM~) subset of TIL that were more acutely responsive to IL-2 and TCR signals and expressed genes reminiscent of early-stage effector-memory cells and central memory cells. In contrast, the CD8^+^BTLA^−^ TIL subset consisted of more late-stage differentiated T~EM~ and T~EMRA~ TIL that were less responsive to IL-2 or TCR signals and exhibited a molecular signature of T-cell deletion.[@cit0013] We also found that the ligation of BTLA on CD8^+^BTLA^+^ TIL with its cognate receptor, herpes virus entry mediator (HVEM), exerted an inhibitory effect on proliferation and cytokine production but also promoted the phosphorylation of Akt and Bad, resulting in an increased expression of Bcl-xL and improved survival of TIL in the presence of apoptotic stimuli. Furthermore, *in vivo* tracking of TCR clones by high-throughput DNA sequencing of the TCR Vβ CDR3 region in patients after TIL ACT showed a greater number of persisting clones originating from the infused CD8^+^BTLA^+^ subset than from the BTLA^−^ subset. Our findings provide a mechanistic basis for the positive clinical association with the CD8^+^BTLA^+^ TIL subset and support a new perspective of T-cell checkpoint molecules as inhibitory signaling systems that inhibit T-cell proliferation and effector function while promoting the survival of these inhibited cells so that critical antigen-specific clones are not depleted from the immune system. This dual functional role of BTLA may explain why CD8^+^ T~EM~ cells accumulate in melanoma while being prevented from further cell division and differentiation.

Results {#s0002}
=======

Differential gene expression profiles between CD8^+^BTLA^+^ and CD8^+^BTLA^−^ melanoma TIL {#s0002-0001}
------------------------------------------------------------------------------------------

To understand the differences between CD8^+^ BTLA^+^ and BTLA^−^TIL we performed expression gene profiling between 2 sorted subsets from 5 different melanoma patients using the Affymetrix^®^ Human Gene 1.0 ST Array. The microarray data have been deposited into the NCBI Gene Expression Omnibus (GEO) database (Accession \# GSE43260). An example of post-sort analysis of CD8^+^BTLA^+^ and CD8^+^ BTLA^−^ TIL subsets and the expression intensity levels of CD3ε and CD3δ are shown in **Figure S1**. As an internal control, we confirmed that expression of the BTLA gene was significantly higher in the sorted CD8^+^BTLA^+^ subset (7.69-fold higher, *P* = 8.80×10^−6^ by paired t test) ([**Fig. 1A**](#f0001){ref-type="fig"}, table). Using arbitrary selection criteria to assess genes that showed a significant difference between the 2 subsets (paired *t* test; fold change ≥1.45; *P* \< 0.05), we identified 406 differentially expressed genes (DEGs). Among these, 171 genes were upregulated in the CD8^+^BTLA^+^ subset and 235 genes were upregulated in the CD8^+^BTLA^−^ subset. In agreement with the previously described phenotype of CD8^+^BTLA^+^ T cells,[@cit0011] we found a significantly increased expression of early effector memory genes (*CD28*: 2.38-fold higher, *P* = 0.025; CD127 \[also known as IL7R\]: 2.08-fold higher, *P* = 0.03)\] and differentiation genes (B3GAT1 \[also known as CD57\]: 1.79-fold higher, *P* = 0.0008)\] ([**Fig. 1A**](#f0001){ref-type="fig"}, table). On the other hand, the CD8^+^ BTLA^−^ subset had significantly increased expression of 13 members of the killer-cell immunoglobulin-like (KIR) receptor gene family and the *TYROBP* gene (also known as DAP12, an adaptor protein for the KIR receptors[@cit0015]; 4.11-fold higher; *P* = 0.0002) ([**Fig. 1A**](#f0001){ref-type="fig"}, table). KIR receptors are known to be expressed by natural killer (NK) cells,[@cit0016] highly differentiated CD8^+^PD-1^−^CD45RA^+^ T~EMRA~ cells in lymphocytes from normal donors,[@cit0017] and senescent human CD8^+^CD28^−^ T cells.[@cit0019] We confirmed the preferential protein expression of some KIR receptors in the CD8^+^BTLA^−^ subset by flow cytometry (**Fig. S2**). We also found that the expression of other genes typically associated with NK cells, such as *NCAM1* (also known as *CD56*; 3.42-fold higher, *P* = 0.01), *LYN* (2.41-fold higher, *P* = 0.025), and *SYK* (1.8-fold higher, *P* = 0.02)\],[@cit0021] was significantly increased in the CD8^+^BTLA^−^ subset ([**Fig. 1A**](#f0001){ref-type="fig"}, table). Lastly, we observed that expression of genes associated with T-cell deletion and anergy,[@cit0014] such as IKAROS family zinc finger 2 (*IKZF2*; 5.08-fold higher, *P* = 0.00076)[@cit0013], early growth response 2 (*EGR2*; 1.82-fold higher, *P* = 0.0185)[@cit0013] and nuclear receptor subfamily, group A, member 3 (*NR4A3*; 1.8-fold higher, *P* = 0.0014)[@cit0013] was also significantly increased in the CD8^+^BTLA^−^ TIL ([**Fig. 1A**](#f0001){ref-type="fig"}, table). Figure 1.CD8^+^BTLA^+^ TIL exhibit a less differentiated, more activated phenotype than their CD8^+^BTLA^−^ counterparts. (**A**) Enrichment analysis of a global set of genes from CD8^+^ BLTA^+^ or BTLA^−^ subsets. The top 50 genes that are immunologically relevant in either the BTLA^+^ or BTLA^−^ subset are shown, ranked by enrichment scores using gene-set enrichment analysis (GSEA). Each row represents 1 gene and each column represents 1 sample of sorted CD8^+^ BTLA^+^ or BTLA^−^ subset from 1 patient. TIL were isolated from melanoma metastases, cultured with 3,000 IU/mL IL-2 for 3 wks and stained for expression of CD8, BTLA, CD45RA, CCR7, CD28, CD27, PD-1, TIM3, granzyme B and perforin. Dead cells were excluded using Aqua^®^ live/dead dye. (**B**, left panel) CD45RA and CCR7 expression on the CD8^+^BTLA^+^ (left dot plot) and CD8^+^BTLA^−^ (right dot plot) populations on a representative TIL from patient 2360. (**B**, right panel) A summary of CD45RA and CCR7 expressions within each CD8^+^BTLA^+^ or CD8^+^BTLA^−^ subset (n=11). Differentiation subsets are defined as follows: T~N~: CD45RA^+^CCR7^+^; T~CM~: CD45RA^+^CCR7^+^, T~EM~: CD45RA^−^CCR7^−^, T~EMRA~: CD45RA^+^CCR7^−^. The results are the percentages of T~EM~ or T~EMRA~ subsets within each gated CD8^+^ BTLA^+^ or BTLA^−^ subset. T~N~ and T~CM~ are omitted because no significant populations were found. (**C**) Summary of the expression of surface markers CD28, PD-1, and TIM3 by the CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets (n ranges from 6--42 per marker). Statistical significance between the subsets was determined using Wilcoxon signed-rank test.

Enrichment of a molecular signature of T cell deletion in the CD8^+^BTLA^−^ TIL subset {#s0002-0002}
--------------------------------------------------------------------------------------

Gene set enrichment analysis (GSEA) was performed to look for enrichment of global or predefined sets of genes in TIL subsets. Given that BTLA has been described as a marker of exhaustion, we wanted to compare gene-set signatures derived from TIL with those derived from CD8^+^ T cells undergoing exhaustion,[@cit0026] deletion,[@cit0013] or anergy.[@cit0013] Interestingly, we did not find enrichment of an exhaustion gene set signature derived from Baitsch et al. (*P* = 0.31)[@cit0026] or Wherry et al. (*P* = 0.50)[@cit0027] in either TIL subset (**Fig. S3**). We also did not find enrichment of a T-cell anergy signature in any of the TIL subsets (*P* = 0.53; **Fig. S3**). However, we did discover enrichment of a molecular signature corresponding to T-cell deletion/tolerance (*P* = 0.00) in the CD8^+^BTLA^−^ TIL subset ([**Fig. 1A**](#f0001){ref-type="fig"}, bottom panel). These results suggest that BTLA does not mark exhausted CD8^+^ TIL; rather, they support the concept that CD8^+^BTLA^+^ TILs represent a less differentiated state of CD8^+^ T~EM~ compared to CD8^+^BTLA^−^ TILs.

Differentiation status of BTLA^+^ and BTLA^−^ CD8^+^ TIL subsets {#s0002-0003}
----------------------------------------------------------------

BTLA has been described as a marker that is progressively downregulated during CD8^+^ T-cell differentiation.[@cit0011] Furthermore, our microarray data suggested that there may be key differences in differentiation state between the BTLA^+^ and BTLA^−^ subsets. Therefore, we analyzed TIL that were expanded *ex vivo* from metastatic tumors by flow cytometric analysis with a panel of differentiation and activation markers. The CD8^+^ T-cell differentiation subsets were broadly defined as follows: naïve T cells (T~N~: CD45RA^+^CCR7^+^), central memory T cells (T~CM~:CD45RA^−^CCR7^+^), effector-memory T cells (T~EM~: CD45RA^−^CCR7^−^), and terminally-differentiated effector T cells re-expressing CD45RA (T~EMRA-int~: CD45RA^lo^CCR7^−^).[@cit0011] Analysis of a representative TIL line for expression of CCR7 *versus* CD45RA to delineate these types of memory cells is shown in [**Fig. 1B**](#f0001){ref-type="fig"}. Overall, there was no statistically significant difference in the percentages of T~EM~ cells within the CD8^+^BTLA^+^ and BTLA^−^ subsets ([**Fig. 1B**](#f0001){ref-type="fig"}, left graph); however, the BTLA^−^ subset was significantly enriched for more differentiated T~EMRA-int~ cells ([**Fig. 1B**](#f0001){ref-type="fig"}, right graph) suggesting that these were more highly differentiated CTL. To further define the memory phenotype of the BTLA^+^ subset, TIL were stained for CD28 and CD27. Within the T~EM~ subset, CD28 and CD27 are markers of early CD8^+^ effector-memory T (T~EM~) cells.[@cit0029] In concordance with the microarray analysis, we found significantly higher expression of CD28 in the BTLA^+^ subset compared to the BTLA^−^ subset (61 ± 6.2% *versus* 45 ± 6.8%; *P* = 0.0008; [**Fig. 1C**](#f0001){ref-type="fig"}). However, the difference in the expression of CD27 between the 2 subsets was not statistically significant (33 ± 4.6% *versus* 36 ± 4.6%, respectively, *P* = 0.455; **Fig. S4A**). Surprisingly, 2 previously reported co-inhibitory markers, PD-1 and TIM3, were also found to be significantly expressed on the CD8^+^BTLA^+^ subset compared to the CD8^+^ BTLA^−^ population; PD-1 expression was 42 ± 4.1% on the BTLA^+^ population *versus* 29 ± 3.4% on the BTLA^−^ cells (*P* = 0.0002; n=42) ([**Fig. 1C**](#f0001){ref-type="fig"}) and TIM3 expression was 22 ± 7.1% on the BTLA^+^ subset compared to 13 ± 4.8% on the BTLA^−^ subset (*P* = 0.015; n = 7) ([**Fig. 1C**](#f0001){ref-type="fig"}). Finally, we examined expression of granzyme B (GB) and perforin (Perf) as markers associated with cytolytic activity. Among the 6 independent lines tested, there was no significant difference between the BTLA^+^ and BTLA^−^ subsets for either cytolytic marker (GB: 95 ± 3.4% *versus* 95 ± 261 2.4%, *p* = 0.438; Perf: 50 ± 9% *versus* 55 ±10%, *P* = 0.688) (**Fig. S4B and C**). Overall, our phenotypic and microarray data suggest that the CD8^+^ BTLA^+^ TIL subset is composed mostly of effector-memory cells (CCR7^−^CD45RA^−^) with a less differentiated (CD28^Hi^) and more activated T-cell phenotype (PD-1^+^ and TIM3^+^) than the BTLA^−^ subset. Interestingly, we found similar levels of GB and Perf expression between the 2 subsets, suggesting there may not be a difference in cytolytic ability between the 2 subsets.

CD8^+^BTLA^+^ TIL exhibit an enhanced proliferative response to IL-2 {#s0002-0004}
--------------------------------------------------------------------

Our initial observation that BTLA^+^ TIL have a less-differentiated T~EM~ phenotype suggested that there may be a significant difference in the response to IL-2 between the CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets. This is important because IL-2 is a key cytokine used in adoptive T-cell therapy to expand and promote the persistence of the TIL *in vivo* after infusion. Therefore, we examined the proliferative and cell survival responses between the 2 subsets. By manual cell counting (based on trypan blue exclusion) after 6 d of culture in the presence of IL-2, we found that CD8^+^BTLA^+^ TIL, on average, had a higher fold expansion than the CD8^+^ BTLA^−^ TIL (TIL 2425: 5.4-fold *versus* 1.4-fold; TIL 2396: 2.2-fold *versus* 0.9-fold; TIL 2486: 1.7-fold *versus* 0.45-fold; [**Fig. 2**](#f0002){ref-type="fig"}, right graph and **Fig. S5C**). Next, we labeled sorted CD8^+^ BTLA^+^ and CD8^+^ BTLA^−^ TIL with carboxyfluorescein succinimidyl ester (CFSE) and cultured the sorted cells with IL-2 for 3 d. Among all patients tested, the BLTA^+^ subset had higher fractions of proliferating cells and had undergone more cell divisions than the BTLA^−^ subset (TIL 2486: 58% *versus* 36%; TIL 2488: 30% *versus* 18%; TIL 2605B: 84% *versus* 53%; TIL 2612: 73% *versus* 8%; [**Fig. 2**](#f0002){ref-type="fig"}, and **Fig. S4B**). Previous studies found that the quantity of the infused CD8^+^CD27^+^ TIL correlated with positive clinical response to ACT in metastatic melanoma.[@cit0030] As shown in **Figure S4**, CD27 was heterogeneously expressed in the BTLA^+^ and BTLA^−^ subsets. Therefore, we examined whether a difference in IL-2 responsiveness was also found between the CD8^+^CD27^+^ and CD8^+^CD27^−^ TIL subsets but did not find a significant difference in proliferation between the sorted CD27^+^ and CD27^−^ subsets (**Fig. S5**). Together, our data suggest that the CD8^+^BTLA^+^ TIL proliferate better than CD8^+^BTLA^−^ TIL in response to IL-2 and that the difference in CD27 expression did not account for this difference in proliferative potential. Figure 2.CD8^+^BTLA^+^ TIL have enhanced proliferation in response to IL-2 stimulation compared to the CD8^+^BTLA^−^ subset. Sorted CD8^+^BTLA^+^ and CD8^+^BTLA^−^ TIL subsets were labeled with carboxyfluorescein succinimidyl ester (CFSE) and cultured at a density of 1 × 10^6^/mL with high-dose IL-2 for 5 d (3,000 IU/mL) (n = 4). (**A**) Histograms showing percentages of proliferating cells from 2 lines (top). The absolute number of cells in each subset was determined using trypan blue exclusion and graphed as fold expansion (bottom). \* indicates significance (*P* \< 0.05) as determined by the Student *t* test.

Enhanced STAT5 activation by CD8^+^BTLA^+^ T-cells in expanding TIL cultures {#s0002-0005}
----------------------------------------------------------------------------

Because the CD8^+^BTLA^+^ subset expanded better with IL-2, we hypothesized that the CD8^+^BTLA^+^ subset might express a higher level of the high-affinity IL-2 receptor, CD25 (IL-2Rα) than the BTLA^−^ subset. Indeed, we found that CD25 expression in TIL expanded with IL-2 tended to be associated with the CD8^+^ BTLA^+^ subset rather than the BTLA^−^ TIL subset from the same patient ([**Fig. 3A**](#f0003){ref-type="fig"}). Further analysis showed that there was a statistically significant difference in the level of cell surface CD25 expression between the CD8^+^BTLA^+^ and BTLA^−^ subsets ([**Fig. 3A**](#f0003){ref-type="fig"}, *P* = 0.002). Next, we asked whether the higher expression of CD25 in the CD8^+^BTLA^+^ subset was associated with stronger signaling induced by IL-2. To answer this question, we measured changes in STAT5 (Y694) phosphorylation, a marker of STAT5 activation downstream of the IL-2 receptor,[@cit0031] in sorted CD8^+^BTLA^+^ and BTLA^−^ TIL. When treated with 200 IU/mL IL-2, CD8^+^BTLA^+^ TIL had higher levels of phospho-STAT5 (change in mean fluorescence intensity \[MFI\]: 205 for TIL 2547 and 739 for TIL 2548) ([**Fig. 3B**](#f0003){ref-type="fig"}). We also performed an IL-2 dose--response study using different doses of IL-2 (0, 50, 200, or 3,000 U/mL) and found that the sorted CD8^+^BTLA^+^ subset had higher expression and MFI of pSTAT5 than the CD8^+^ BTLA^−^ subset at all doses of IL-2 tested ([**Fig. 3**](#f0003){ref-type="fig"}, n = 4). Thus, IL-2 triggers a more robust signal activating STAT5 downstream of the IL-2R in the CD8^+^BTLA^+^ TIL subset, which may promote higher levels of CD25 expression in an autocrine loop. Figure 3.Enhanced IL-2 responsiveness by CD8^+^BTLA^+^ TIL. (**A**) TIL were stained for expression of CD8, BTLA, and CD25 and with the Aqua^®^ live/dead viability dye. The left dot plot shows representative staining of TIL 2538 and 2547. The numbers indicated percent expression within the AQUA^−^CD8^+^ population. The right graphs summarize the percentage CD25 expression and CD25 mean fluorescence intensity (MFI) for the CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets (n = 23). *P* value was calculated using Wilcoxon signed-rank test. (**B**) TIL were sorted into CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets and cultured with increasing concentrations of IL-2 for 20 min. Cells were fixed, permeabilized, and stained for pStat5 (Y694). The left histograms show the level of pSTAT5 (Y694) expression after treatment with 200 IU/mL IL-2 for 20 min. The change in MFI (ΔMFI) between the subsets is shown. The top graphs show the change in percent pSTAT5 levels after incubation with increasing concentrations of IL-2 for 3 independent TIL lines. The shift in pSTAT5 MFI was determined by subtracting the baseline levels for each subset (n = 4). Statistical significance was determined using a paired Student *t* test.

CD8^+^BTLA^+^ TIL have superior responses to TCR stimulation and produce more IL-2 {#s0002-0006}
----------------------------------------------------------------------------------

The results above suggested that the BTLA^+^ TIL had a heightened response to IL-2. Next, we explored the relative capacity of the BTLA subsets to respond to TCR triggering. The proliferative response of CD8^+^BTLA^+^ and BTLA^−^ T cell subsets after TCR stimulation was first analyzed. We also examined the induction of activation markers and the capacity of the 2 subsets to produce IL-2, a key feature of early-differentiated CD8^+^ memory T cells in humans.[@cit0032] We first compared the proliferation of the sorted CD8^+^BTLA^+^ and BTLA^−^ subsets stimulated with plate-bound anti-CD3 plus anti-CD28 (OKT3 + CD28) in a ^3^\[H\]-thymidine incorporation assay in the absence of exogenous IL-2. As shown in [**Fig. 4A**](#f0004){ref-type="fig"}, we consistently noted significantly higher proliferation in the CD8^+^BTLA^+^ subset in 4 different TIL lines. Next, we assessed the induction of the key activation markers CD25, PD-1, and LIGHT in response to the same TCR stimulation. Although both CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets could induce expression of PD-1 upon stimulation, expression of LIGHT was generally unchanged in BTLA^−^ cells but modestly upregulated in BTLA^+^ cells ([**Fig. 4B**](#f0004){ref-type="fig"}). However, the most dramatic and consistent difference was in the markedly greater increase in CD25 expression by CD8^+^BTLA^+^ cells ([**Fig. 4B**](#f0004){ref-type="fig"}). Finally, in sorted CD8^+^ BTLA^+^ and BTLA^−^ subsets from 2 different patients, we detected more intracellular IL-2 in CD8^+^BTLA^+^ TIL than in the CD8^+^BTLA^−^ subset when stimulated with PMA and ionomycin (TIL 2547 ΔMFI: 274; TIL 2538 ΔMFI: 652) ([**Fig. 4C**](#f0004){ref-type="fig"}). However, there was no difference in the secretion of the other cytokines tested or in CTL function using either a redirected lysis assay or in response to autologous melanoma tumor cells (**Fig. S6**). Thus, our data showed that, although there was no difference in CTL function between the subsets, stimulation of the TCR signaling pathway induced higher CD25 levels and triggered more autocrine IL-2 production in the CD8^+^BTLA^+^ TIL subset, which might have contributed to the increased TCR-induced proliferative response. Figure 4.CD8^+^BTLA^+^ TIL are more responsive to TCR stimulation and produce more IL-2. (**A**) Sorted CD8^+^BTLA^+^ and CD8^+^BTLA^−^ cells were stimulated with plate-bound anti-CD3 (OKT3) and anti-CD28 (OKT3+CD28) or not stimulated (NIL) in the absence of IL-2 for 3 d Cells were pulsed with 1 μCi of \[^3^H\]-thymidine for the last 18 h of culture. Results were shown as counts per minute (cpm) from triplicate wells (mean ± SD). \* indicates significance (*P* \< 0.05) as determined by Student *t* test. (**B**) Sorted CD8^+^ BTLA^+^ and CD8^+^BTLA^−^ subsets were stimulated with 200 IU/mL IL-2, OKT3, or OKT3 plus CD28 for 72 h. Cells were analyzed for expression of CD25, LIGHT, and PD-1 by flow cytometry. The percent expression of each marker is shown. (**C**) Sorted CD8^+^ BTLA^+^ and CD8^+^BTLA^−^ subsets were stimulated with PMA and ionomycin for 4 h and stained for expression of intracellular IL-2. The numbers indicate the MFI for each subset from 2 TIL lines.

Tracking the persistence of CD8^+^BTLA^+^ and CD8^+^BTLA^−^ T-cell clones *in vivo* {#s0002-0007}
-----------------------------------------------------------------------------------

The gene expression and functional data presented thus far suggested a less differentiated and more activated phenotype of the CD8^+^ BTLA^+^ TIL subset. Thus, we hypothesized that CD8^+^ BTLA^+^ TIL have longer persistence *in vivo* after adoptive transfer into treated patients, which might explain the positive association with clinical response.[@cit0002] We were interested in tracking how unique T-cells clones arising from the infused BTLA^+^ and BTLA^−^ cells persisted after infusion into patients *in vivo*. To this end, we collected DNA from sorted CD8^+^BTLA^+^ and BTLA^−^ subsets from the infusion product of 2 TIL-treated patients and from peripheral blood mononuclear cells (PBMCs) at multiple time points post-infusion and examined the persistence of individual clones using high-throughput CDR3 sequencing technology (Adaptive Biotechnologies, Seattle, WA) ([**Fig. 5**](#f0005){ref-type="fig"}). CDR3 sequencing of the TCR Vβ allows identification of T cells without knowing their specificities. BTLA subsets from the infusion product were used as a starting point to identify cells present in the infusion product rather than the endogenous T cells that were reconstituted in the patient following lymphodepletion. Both patients responded to TIL therapy according to RECIST[@cit0033] and immune-related response criteria (irRC).[@cit0034] Figure 5.*In vivo* tracking of infused CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets. TIL (100 × 10^6^ cells) from the infusion product of treated patients were sorted into bulk CD8^+^ and CD8^+^ BTLA^+^ and CD8^+^BTLA^−^ subsets and flash frozen. PBMCs collected at the labeled time points were treated in the same manner. DNA was isolated from the banked samples as described in Methods and sent for CDR3 sequencing at Adaptive Biotechnologies. (**A**) Vβ TCR diversity shown as pie charts for each subset with the total number of Vβ clonotypes found. (**B**) Overlap of each CDR3 sequence for the sorted CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets from the infusion product. Overlapping CDR3s are shown in blue, whereas CDR3 sequences found only in the CD8^+^BTLA^+^ subset are shown in red, and those found only in the CD8^+^BTLA^−^ subset are shown in green. The axis shows the frequency of each CDR3 sequence for each subset within the infusion product. The percentage of the infusion product consisting of overlapping subsets is indicated. (**C**) Frequency of the unique CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets present in the blood over time.

Examination of the TCR Vβ family diversity in the infused CD8^+^ TIL for each patient showed that the BTLA^+^ cells had a similar Vβ diversity to the BTLA^−^ cells ([**Fig. 5A**](#f0005){ref-type="fig"}). To determine whether the BTLA subsets were comprised of T cells with different specificities, CDR3 sequences for each subset from the infusion product were compared ([**Fig. 5B**](#f0005){ref-type="fig"}). The majority of the CDR3 sequences from the infusion product overlapped between subsets for both patients (95.2% and 92.9% of CDR3 sequences overlapped between both subsets in each respective patient), supporting the concept that BTLA does not mark different clones but acts as a differentiation marker. However, as we were interested in tracking each subset in the blood of patients over time following infusion, only CDR3 sequences unique to each subset were examined (unique BTLA^+^, red circles; unique BTLA^−^, green circles). This approach of identifying unique clones was the only way of analyzing the relative persistence of each subset. The sum of all CDR3 sequences found independently within each subset was calculated as a percentage of the total number of CDR3 sequences found in the peripheral blood at each time point to separate the endogenous T cells within the blood from the infused T cells. [**Figure 5C**](#f0005){ref-type="fig"} shows that, in both patients, the frequency of total CD8^+^BTLA^−^ T cells remained low (less than 1%) over all time points. However, the CD8^+^ BTLA^+^ T cells expanded and persisted at a higher frequency at the later time points. Thus, in these 2 responding patients, unique clones from the infused CD8^+^BTLA^+^ subset exhibited superior long-term persistence in the peripheral blood *in vivo*.

BTLA ligation provides a prosurvival signal in TIL and enhances Bcl-xL expression {#s0002-0008}
---------------------------------------------------------------------------------

Our results so far underscore the fact that BTLA is a marker for less differentiated cells that have an enhanced responsiveness to IL-2 as well as enhanced persistence *in vivo* after infusion into patients. However, BTLA signaling is considered to be suppressive as its ligation has previously been shown to result in the recruitment of SHP1/2 phosphatases and decreased cell proliferation and cytokine secretion.[@cit0005] We therefore set out to determine whether BTLA signaling in our melanoma TIL was suppressive. In fact, similar to other studies using PBMC or TIL derived from tumor-draining lymph nodes, ligation of sorted CD8^+^ BTLA^+^ TIL *in vitro* using a plate-bound HVEM-Fc fusion protein together with anti-CD3 antibody resulted in a marked decrease in proliferation (8% *versus* 32%) and lower production of the proinflammatory cytokines IFN-γ and TNF-α compared to the control human IgG after 3 d of stimulation (**Fig. S7**). However, in an experiment examining the effects of CD3 and BTLA co-ligation using a TIL co-culture system with HVEM-expressing L cells loaded with anti-CD3 antibody we observed that the TIL were protected from cell death ([**Fig. 6A**](#f0006){ref-type="fig"}, *P* = 0.009). As HVEM signaling has been shown to produce a prosurvival signal via the NF-κB signaling cascade, we stained the sorted CD8^+^BTLA^+^ or BTLA^−^ subsets after co-culture with L cells for loss of IκBα as a read-out for NF-κB activation. Although a small loss was detected compared to the unstimulated control, there was no difference between the subsets cultured on either CD32-L cells or HVEM-L cells (**Fig. S8A**). To rule out any effect of signaling kinetics, we used another experimental system in which sorted TIL were cultured on plate-bound anti-CD3 (OKT3) with a control Ig, HVEM-Fc, or BTLA-Fc for 96 h and assessed for apoptosis. Using this model, only the CD8^+^BTLA^+^ TIL cultured with HVEM-Fc co-stimulation were protected from activation-induced cell death (AICD) (**Fig. S8B**). This provides further evidence that the survival phenotype was not mediated by HVEM signaling because BTLA-Fc (ligating HVEM) did not protect from apoptosis. Furthermore, examination of antiapoptotic proteins Bcl-xL, Bcl-2, and Bcl-6 after HVEM-L cell co-culture showed a significant increase in the level of Bcl-xL in the CD8^+^ BTLA^+^ TIL ([**Fig. 6B**](#f0006){ref-type="fig"}, *P* = 0.043). Bcl-xL is an analog of Bcl-2 that has been shown to be induced by CD28 co-stimulation and mediates cell survival.[@cit0035] Interestingly, BTLA ligation on CD4^+^ T cells has been shown to result in a gene signature similar to that induced by CD28 and ICOS co-stimulation in terms of antiapoptotic gene expression.[@cit0009] This suggests that BTLA signaling on CD8^+^ T cells may, in fact, provide both a positive and negative signal. Figure 6.For figure legend, see page 10.**Figure 6 (see previous page)**. BTLA ligation provides a prosurvival signal to TIL. (**A**) CD32^+^ L cells or CD32^+^HVEM^+^ L cells (HVEM L cells) were pulsed with 200 ng/mL OKT3 and cultured with TIL (1×10^6^/mL) in the presence of 100 IU/mL IL-2. After 5 days, TIL were harvested and stained for CD8, Annexin V, and 7-AAD. The left dot plots show representative staining of a TIL line gated on CD8^+^ cells. The right graph shows the percentage of apoptosis among all lines tested. Statistical significance was determined using a Wilcoxon signed-ranked test. (**B**) Sorted CD8^+^ BTLA^+^ TIL were cultured with L cells as in (A) and stained for Bcl-xL, Bcl-6, and Bcl-2 after 5 d (n = 4). (**C**) TIL were sorted into CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets and stimulated for 2 h with 30 ng/mL OKT3 and 10 μg/mL HVEM-Fc (plate-bound) (HVEM-Fc+OKT3), 10 μg/mL anti-BTLA blocking antibody, 3B1 (HVEM-Fc+OKT3+3B1), and 10 nM PI3K inhibitor (GSK2126458) (HVEM-Fc+OKT3+PI3Ki). TIL cultured alone or with OKT3 and a control Ig were included as negative controls. TIL were immediately fixed with prewarmed Phosflow Fix buffer I for 10 min at 37°C, permeabilized with pre-chilled Phosflow Perm buffer III, and stained with pAkt (S473) for 30 min on ice. The left histograms show representative staining from TIL 2619. The right graphs show the fold change in percent pAkt expression normalized to the TIL-alone condition (set to 1; n = 3 TIL lines). Statistical significance was determined using a 2-tailed paired Student *t* test. (**D**) CD8^+^ BTLA^+^ TIL were cultured with 30 ng/mL OKT3 plus control Ig (Ctl Ig), OKT3 plus 10 μg/mL HVEM-Fc (HVEM-Fc), or OKT3 plus 10 μg/mL BTLA-Fc (BTLA-Fc) for 24 and 96 h. Cells were stained for the presence of pBad by intracellular flow cytometry as described in Methods.

BTLA ligation induces pAkt and maintains Bad in a phosphorylated state {#s0002-0009}
----------------------------------------------------------------------

The above prosurvival phenotype led us to ask whether BTLA may also have a prosurvival signaling function mediated by HVEM binding in human melanoma TIL. This could potentially occur through the conserved YXN motif upstream of the ITIM and ITSM motifs in BTLA.[@cit0005] In the platelet-derived growth factor (PDGF) receptor, this YXN motif has been found to bind to the signaling adaptor protein Grb-2 following phosphorylation of the tyrosine, leading to recruitment of phosphatidylinositol 3' kinase (PI-3K) and activation of Akt through serine phophorylation.[@cit0008] This suggests that HVEM-BTLA signaling could in fact have a prosurvival effect on TIL. To directly test whether BTLA ligation results in initiation of a prosurvival signal via phosphorylated Akt (pAkt), TIL were sorted into CD8^+^ BTLA^+^ and CD8^+^ BTLA^−^ subsets and stimulated *in vitro* with HVEM-Fc fusion protein and anti-CD3 antibody. Ligation of BTLA resulted in a significant increase in the level of detectable pAkt (expressed as fold change over that of TIL stimulated with anti-CD3 without HVEM-Fc, which was arbitrarily set to 1) compared to the control Ig (Ctl Ig) with anti-CD3 (*P* = 0.017) ([**Fig. 6C**](#f0006){ref-type="fig"}). Furthermore, this was specific for HVEM ligation of BTLA as preblockade of BTLA using the blocking monoclonal anti-BTLA antibody 3B1 (Genentech) significantly reduced the induction of pAkt in the presence of HVEM-Fc (*P* = 0.02) to levels comparable to that of the control Ig ([**Fig. 6C**](#f0006){ref-type="fig"}). This activation of Akt was mediated through the PI3K pathway as addition of the pan-PI3K inhibitor GSK2126458 did not result in phosphorylation of Akt, with levels remaining similar to those with TIL alone ([**Fig. 6C**](#f0006){ref-type="fig"}). To further confirm that the increased pAkt was due to signaling via BTLA, sorted CD8^+^BTLA^−^ cells were also stimulated with control Ig or HVEM-Fc in the presence of anti-CD3 antibody and no significant differences in the fold change of pAkt (TIL alone levels set to 1) were observed (*P* = 0.61) (**Fig. S9**). To further elucidate the antiapoptotic role of BTLA ligation, we examined the extent of Bad phosphorylation, a downstream effect of PI3 kinase/Akt signaling. Phospho-Bad (pBad) cannot bind to Bcl-xL and Bcl-2, leaving them free to sequester Bax and Bak and prevent the release of cytochrome C from the mitochondria.[@cit0037] Indeed, when sorted CD8^+^BTLA^+^ TIL were stimulated with anti-CD3 and HVEM-Fc, pBad levels remained high at 24 h post stimulation compared with the Ctl Ig and BTLA-Fc co-stimulatory conditions ([**Fig. 6D**](#f0006){ref-type="fig"}). pBad levels were also higher in the HVEM-Fc co-stimulated cells at 96 h after stimulation ([**Fig. 6D**](#f0006){ref-type="fig"}).

Collectively, these results suggest that in the presence of TCR stimulation, BTLA ligation by HVEM facilitates survival signals in CD8^+^ TIL mediated through PI3K/Akt, maintenance of pBad, and induction of Bcl-xL. This would be important in the context of antigen presentation by dendritic cells or melanoma tumor cells, both of which express HVEM.[@cit0006]

Discussion {#s0003}
==========

The data presented in this paper provide a mechanistic basis for our recent findings from a Phase II clinical trial demonstrating that BTLA as a biomarker on adoptively-transferred TIL was associated with a positive clinical response to ACT with TIL in patients with metastatic melanoma.[@cit0002] We made a number of striking observations supporting a new and more complex view of the role of BTLA in activated effector-memory CD8^+^ T cells, not only as a marker of less-differentiated and functional T cells, but also possibly as a dual co-inhibitory and cell survival signaling molecule in human T cells. In addition, in 2 melanoma patients that responded to TIL therapy, we found that T-cell clones unique to the CD8^+^BTLA^+^ subset persisted longer *in vivo* in the blood after infusion and showed evidence of expansion, whereas clones associated with the BTLA^−^ subset progressively disappeared or did not expand.

A key feature of the CD8^+^BTLA^+^ subset was its higher constitutive and TCR-induced upregulation of CD25 and autocrine production of IL-2. The ability of the BTLA^+^ TIL to produce more of their own IL-2 was associated with higher rates of cell division than in BTLA^−^ cells; these are critical attributes for CD8^+^ memory T-cells to survive long term and maintain effector function after an immune response. Our findings were concordant with a previous study on memory CD8^+^ T cells in which memory CD8^+^CD25^+^ T cells both produced and responded to IL-2 in response to a variety of antigens, whereas the CD8^+^CD25^−^ memory T cell population responded to fewer antigens and did not proliferate in response to stimulation with IL-2.[@cit0032] The ability of the CD8^+^ BTLA^+^ subset to produce more IL-2 could therefore endow them with the preferential ability to expand and persist *in vivo* after infusion into patients.

Another observation in this study was that CD8^+^ BTLA^+^ melanoma TIL had a highly activated, yet less differentiated, effector-memory (T~EM~) phenotype compared with their BTLA^−^ counterparts. This was supported by differential gene expression studies on the sorted subsets revealing that the CD8^+^BTLA^+^ TIL were less differentiated through higher expression of memory markers such as CD28, CD25, and IL-7R. In contrast, BTLA^−^ cells had markedly higher expression of multiple NK markers, including multiple killer cell lectin-like receptor (KLR) family members, such as KLRG1 and KLRD1, and killer-inhibitory receptor (KIR) family members, as well as DAP12.

We also observed that CD8^+^BTLA^−^ TIL, although hyporesponsive to proliferative signals, nevertheless maintained a similar cytotoxic capability to the CD8^+^BTLA^+^ TIL. This phenomenon may be due to the unique signaling of KIRs on human CD8^+^ T cells; previous studies have found that their presence on CD8^+^CD28^−^ T cells, unlike NK cells, only inhibits complex cellular functions such as proliferation, while leaving certain effector functions such as cytotoxicity essentially intact, presumably because of delayed recruitment to the TCR synapse after activation.[@cit0039] Additionally, although there was discordance between enrichment of multiple KIR gene transcripts in the CD8^+^BTLA^−^ TIL and a few KIRs being expressed at the protein level in our present study, this might be explained by recent findings in which human CD8^+^ T cells, unlike NK cells, were found to generally express only one activating or inhibitory KIR.[@cit0040]

Our gene expression studies also give some insights into the issue of inhibitory receptors and CD8^+^ T-cell exhaustion. Interestingly, we found significant enrichment of a T-cell deletion/tolerance signature in the CD8^+^BTLA^−^ subset, supporting the more differentiated and hyporesponsive nature of these BTLA^−^ cells. Although a significant proportion of the CD8^+^BTLA^+^ TIL expanded from melanoma metastases co-expressed PD-1 and TIM3, we found no significant enrichment of genes related to CD8^+^ T-cell exhaustion when we used GSEA to query 2 published gene sets: one on exhausted PD-1-expressing CD8^+^ T cells isolated after chronic LCMV infection in mice and the other on exhausted human PD-1^+^ melanoma antigen-specific (MART-1) CD8^+^ T cells.[@cit0026] These previously published exhaustion genes were not enriched in the sorted BTLA^−^ TIL subset either, but these cells were characterized by a T-cell deletion gene profile as mentioned above. In addition, unlike PD-1 and TIM3, BTLA itself has not been found to be significantly enriched or overexpressed in these previously published exhaustion gene sets. Similarly, BTLA was not found to be overexpressed in a gene expression profile present in exhausted CD8^+^ T cells from HIV-infected patients.[@cit0017] It should be noted that our gene expression profiling was performed after a period of expansion of isolated TIL with IL-2 in order to generate enough cells for analysis. This may have reversed an exhausted state and its associated gene expression profile in the BTLA^+^ cells that may have been detectable if the TIL were analyzed directly *ex vivo*. Nevertheless, our results do support the view that, in the context of adoptive cell therapy, expanded TIL may not conform to the current T-cell exhaustion paradigm. Rather, expansion leads to T-cell differentiation and loss of responsiveness to IL-2 and TCR stimulation, as reflected in the expression of genes associated with T-cell deletion. A BTLA^−^ phenotype is a key marker of this transition to a more differentiated, less cytokine-responsive state. This also supports our TCR clone tracking data in 2 responding patients using TCR Vβ CDR3 region sequencing, in which where unique clones associated with CD8^+^BTLA^+^ cells had superior persistence *in vivo* after TIL infusion. Our finding here is concordant with other reports showing that persistence of the infused TIL clones was a key factor associated with positive clinical response after ACT.[@cit0042]

Our TCR Vβ CDR3 region sequencing studies, which tracked unique and shared T-cell clones in TIL from the CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets, showed that the subsets shared a majority of clones, although unique clones could also be detected in each subset (which allowed us to track the relative persistence of each subset *in vivo* in the patients). The presence of shared clones in the subsets suggests that BTLA^+^ and BTLA^−^ cells represent discrete stages of effector-memory CD8^+^ T-cell differentiation, with the BTLA^−^ subset representing a more differentiated stage toward terminal differentiation (as supported by our functional studies). The detection of unique clones in each subset may reflect differential localization of BTLA^+^ and BTLA^−^ cells from the same clonal population, leading to the presence of one subset or the other in the tumor-infiltrating lymphocyte compartment. This will need to be further investigated in future studies.

The improved persistence of BTLA^+^ cells *in vivo* may be modulated by increased expansion, but might also due to increased cell survival linked to BTLA signaling or an intrinsic cell death-resistant phenotype. A prosurvival role of BTLA was initially observed in a chronic GvHD model in which adoptively transferred BTLA^−/−^ splenocytes initially expanded in recipient mice but could not persist long term, suggesting that the memory T-cell function was compromised.[@cit0036] Recently, another study showed a prosurvival role of BTLA *in vivo* in a mouse model of vaccinia virus.[@cit0043] In this model, however, BTLA mediated survival and memory development through its expression on dendritic cells. We also observed a prosurvival signaling effect of BTLA through ligation with HVEM, in which we consistently saw a reduction in apoptosis in the activated TIL. Although we found that LIGHT was upregulated on CD8^+^ TIL after TCR activation and could potentially interact with HVEM, a prosurvival effect mediated through LIGHT is unlikely because it has no obvious signaling motif,[@cit0044] and it has been reported that signaling through HVEM upon binding to LIGHT might induce a different T-cell survival via NF-κB activation.[@cit0045] It is also possible that *cis* interaction or a T-T interaction between BTLA and HVEM could mediate survival via HVEM, as shown by Carl Ware\'s group.[@cit0046] However, in our system using BTLA-Fc for co-stimulation, we failed to see protection from AICD and maintenance of pBad. Furthermore, we were unable to detect NF-κB activation at early time points using our L cell system, as measured indirectly via IκB downmodulation. Thus, our results indicate that the CD8^+^BTLA^+^ TIL subset, in addition to being less differentiated and more cytokine responsive, may have improved survival capabilities through BTLA ligation. The loss of BTLA in a more highly differentiated state, leading to a loss of prosurvival Akt activation, may contribute to the enrichment of the T-cell deletion gene signature[@cit0013] in the CD8^+^BTLA^−^ TIL.

Mechanistically, the ability of BTLA to activate Akt and cell survival and its co-inhibitory activity during TCR activation limiting cell division and cytokine secretion can be reconciled based on its unique structural properties. Although human BTLA is similar to PD-1 in possessing a consensus ITIM and ITSM site for SHP1/2 docking as well as functioning as a monomer, it has a putative Grb-2 binding domain consisting of a YXNX motif upstream of the ITIM- and ITSM-containing domains that is not found in PD-1. Early *in vitro* experiments found that a synthesized 11-mer phospho-tyrosine peptide containing this domain with a phosphorylated tyrosine 226 residue from BTLA could recruit Grb-2-PI3K.[@cit0008] Grb-2 has also been found to be able to recruit PtdIns-3K via its interaction with c-Cbl after TCR crosslinking on Jurkat T cells.[@cit0047]

These observations and concepts suggest that BTLA signaling may also lead to a scenario in cancer where, in the context of chronic antigen stimulation within the tumor microenvironment, BTLA ligation by melanoma tumors that express HVEM[@cit0006] may inhibit or arrest further cell division and differentiation of CD8^+^ TIL while enhancing their survival, leading to their accumulation in an incompletely differentiated state in tumors. This would explain why we and others have found that the vast majority of CD8^+^ TIL in melanoma are in an early effector-memory state of differentiation with few fully differentiated CTL, as well as the better persistence of TIL expressing BTLA after adoptive transfer in our clinical trials.

In summary, our study provides a molecular basis for our previously observed correlation between positive clinical outcome and CD8^+^BTLA^+^ TIL after adoptive transfer in patients with metastatic melanoma. Our data show that this effect is due to a less-differentiated state of the CD8^+^BTLA^+^ TIL subset, their ability to receive prosurvival signals through BTLA, and their ability to persist better after adoptive transfer *in vivo*.

Materials and Methods {#s0004}
=====================

Expansion of tumor-infiltrating lymphocytes from human melanoma tumors {#s0004-0001}
----------------------------------------------------------------------

TIL were separated from tumor cells and expanded in high-dose IL-2 (6,000 IU/mL, Novartis) as described previously.[@cit0019] Autologous primary melanoma tumor lines were also established by collecting cells at the 75% Ficoll layer and were used as targets in cytotoxic T lymphocyte assays.

Flow cytometry {#s0004-0002}
--------------

TIL were stained using the Live/Dead^®^ Fixable Aqua Dead Cell Stain Kit (Life Technologies, CA) according to the manufacturer\'s instructions. Cells were stained with a combination of antibodies (from BD unless indicated otherwise) against the following proteins: CD3 FITC (SK7), CD4 PerCP-Cy5.5 (RPT-T4), CD8 PB (RPT-T8), BTLA PE (J168), TIM3 APC (F38--2E2), PD-1 PerCP-Cy5.5 (EH12.2H7), CD27 APC-H7 (M-T271), CD28 PE-Cy7 (CD28.2), CD45RA FITC 566 (HI100), CD158a FITC, CD158b FITC, CD158e APC, NKG2D APC, NKAT2 FITC, NKB1 FITC, APC-conjugated MART-1 peptide (ELAGIGILTV) HLA-A2.1 tetramer (Beckman Coulter), and APC-conjugated gp100 peptide (IMDQVPFSV) HLA-A2.1 tetramer (Beckman Coulter). For all flow cytometry assays, data were acquired using a FACScanto II cytometer (BD Biosciences), and analyzed using FlowJo software (Treestar version 7.6.5).

Cell sorting {#s0004-0003}
------------

TIL were stained for CD8, BTLA, and CD27 and sorted using an Aria II or Influx cell sorter (BD Biosciences) directly into TIL media. Only populations with ≥95% post-sort purity were used for experiments.

Phospho-flow cytometry {#s0004-0004}
----------------------

Sorted cells were stimulated with increasing doses of IL-2 (50 U/mL, 200 U/mL, and 3,000 U/mL) for 20 min. At the end of the stimulation, cells were fixed in BD™ Cytofix Buffer for 10 min and permeabilized by chilled BD™ Phosphoflow™ Perm Buffer III for 20 min at 4°C. Cells were washed twice with BD™ PharMingen™ Stain Buffer and stained with fluorochrome-conjugated anti--phospho-Stat5 (Tyr694) antibody for 20 min at 4°C prior to analysis.

Intracellular cytokine staining {#s0004-0005}
-------------------------------

Sorted cells were stimulated with 25 ng/mL PMA and 1 μg/mL ionomycin in the presence of BD GolgiStop^TM^ according to the manufacturer\'s instructions. After 4 h, the cells were fixed and permeabilized using BD Cytofix/Cytoperm^TM^ kit and subsequently stained with IL-2 PerCP-Cy5.5, IFN-γ (PE-Cy7), and TNF-α APC antibodies.

Microarray {#s0004-0006}
----------

Total RNA was isolated from sorted CD8^+^ TIL subsets using a RNeasy Mini Kit (Qiagen, Valencia, CA USA). Samples were hybridized to Human Gene ST 1.0 Arrays (Affymetrix, Santa Clara, CA). Raw data that passed QC assessment were generated with Affymetrix GeneChip Command Console and imported into BRB-ArrayTools v4.2.1 (NCI, Bethesda, 587 MD USA), normalized with robust multi-array average (RMA) algorithm, and log~2~ transformed. The microarray data have been deposited into the NCBI GEO database (Accession \#GSE43260; <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43260>).

Costimulation of TIL with HVEM+ L cells or HVEM-Fc fusion protein {#s0004-0007}
-----------------------------------------------------------------

CD32^+^ or CD32^+^ HVEM^+^ L cells were harvested, pulsed with 200 ng/mL OKT3 and co-cultured at a 1:1 ratio with TIL. After 12 h, TIL were harvested and stained for CD8 and intracellular IκBα PerCP-Cy5.5 (BD). After 5 days, TIL were stained for CD8, 7-AAD, Annexin-V, Bcl-xL Alexa 488 (Cell Signaling), Bcl-2 FITC (BD), and Bcl-6 PerCP-Cy5.5 (BD). Additionally, sorted CD8^+^ BTLA^+^ and BTLA^−^ TILs were stimulated with 30 ng/mL plate-bound OKT3 and 10 μg/mL control human Ig, BTLA-Fc (R&D), or HVEM-Fc (R&D) with or without 10 μg/mL soluble anti-BTLA blocking mAb (clone 3B1) or PI3K inhibitor (10 nM GSK2126458). Cells were stained as described above.

Tracking TCR clonotypes in patients infused with TIL {#s0004-0008}
----------------------------------------------------

TIL from the infusion product of patients treated with ACT at MD Anderson were sorted into CD8^+^BTLA^+^ and CD8^+^BTLA^−^ subsets. Cell pellets were flash frozen and stored at −80°C. Peripheral blood mononuclear cells were collected post-infusion for tracking of the infused cells. Total DNA was isolated using the Qiagen AllPrep Kit^TM^ and samples were shipped to Adaptive Biotechnologies (Seattle, WA USA) for sequencing of the T cell CDR3 region using the ImmunoSEQ^TM^ assay.

Statistical analysis {#s0004-0009}
--------------------

For quantitative comparisons between 2 paired groups, Wilcoxon signed-rank test (2-sample, 2-tailed comparisons) was performed with Graph Pad Prism v5.0 (La Jolla, CA) with column statistics reported as mean ± S.E; *P* \< 0.05 was considered statistically significant. *P* values and FDRs for gene sets used in GSEA were calculated with 1,000 permutations by phenotype. Enrichment of a particular gene set in an indicated subset of CD8^+^ TIL was considered significant if *P* \< 0.05 and FDR \< 0.25. We also used a comprehensive software package, BRB-ArrayTools v4.2.1 (NCI, Bethesda, MD USA), to determine statistically significant genes (*P* \< 0.05) between CD8^+^ BTLA^+^ and CD8^+^BTLA^−^ TIL subsets using a paired Student *t* test.

Patient tumor sample acquisition {#s0004-0010}
--------------------------------

Tumor samples were obtained from patients with Stage IIIc and Stage IV melanoma undergoing surgery at The University of Texas MD Anderson Cancer Center according to an Institutional Review Board-approved protocol and with patient consent (IRB\# LAB06--0755 and LAB06--0757). **Table S1** shows the characteristics of the melanoma patients, including patient age, sex, tumor location, disease stage, and anatomical sites.
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